Protein News and Research

RSS

Proteins are complex molecules that are made up of amino acids. They can be found in every cell in the body, and carry out vital processes that keep human beings alive. Mutations in proteins can lead to a multitude of diseases, the most common being cancer.

Novel strategy to build molecular probes may lead to development of new cancer drugs

Chemical engineers at UC Santa Barbara expect that their new process to create molecular probes may eventually result in the development of new drugs to treat cancer and other illnesses.

7 Apr 2011

OncoGenex, Teva's custirsen preclinical data in CRPC presented at AACR meeting

Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that new preclinical data of their investigational compound custirsen in castrate resistant prostate cancer were presented this week at the 102nd Annual Meeting of the AACR.

7 Apr 2011

Molecular switch regulating protein behavior increases human susceptibility to schizophrenia, mood disorders

Johns Hopkins researchers report the discovery of a molecular switch that regulates the behavior of a protein that, when altered, is already known to increase human susceptibility to schizophrenia and mood disorders.

7 Apr 2011

Vegans at increased risk of developing blood clots and atherosclerosis

People who follow a vegan lifestyle - strict vegetarians who try to eat no meat or animal products of any kind - may increase their risk of developing blood clots and atherosclerosis or "hardening of the arteries," which are conditions that can lead to heart attacks and stroke. That's the conclusion of a review of dozens of articles published on the biochemistry of vegetarianism during the past 30 years. The article appears in ACS' bi-weekly Journal of Agricultural and Food Chemistry.

7 Apr 2011

New insight into Huntington's disease

Huntington's disease has long been linked to jerky movements. Now, researchers in Lund, Sweden, have shown that the metabolism can also be seriously affected by the hereditary disease. The new laboratory findings provide hope of entirely new treatment methods.

7 Apr 2011

Scientists identify cellular switch that may help treat cardiovascular disease, cancer

Scientists at the University of Hull have identified a cellular 'on-off' switch that may have implications for treating cardiovascular disease and cancer.

7 Apr 2011

Study: New cancer drug shrinks tumors in mouse model with few side effects

A study led by researchers at the University of Michigan Comprehensive Cancer Center showed in animal studies that new cancer drug compounds they developed shrank tumors, with few side effects.

7 Apr 2011

Nuron Biotech announces acquisition of Wyeth's HibTITER vaccine assets

Nuron Biotech Inc., a specialty biologics and vaccines company, today announced that it has acquired assets relating to the vaccine HibTITER from Wyeth LLC, a wholly owned subsidiary of Pfizer Inc, for the U.S. and many other markets, including Japan and Korea. Financial terms of the sale were not disclosed.

7 Apr 2011

Avila announces successful completion of AVL-292 Phase 1a clinical studies for B-cell cancers

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today announced that it has successfully completed two Phase 1a clinical studies for AVL-292, its orally-available, selective inhibitor of Bruton's tyrosine kinase (Btk).

6 Apr 2011

ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumours

Circadian Technologies announced today that its licensee ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, has advised that it has commenced the first Phase 1 clinical trial of its fully-human monoclonal antibody IMC-3C5.

6 Apr 2011

BioWa, OBT enter license agreement to advance ADCC programs

BioWa, Inc. and Oxford BioTherapeutics Ltd today announced that they have entered into a license agreement to provide OBT with access to BioWa's patented POTELLIGENT Technology platform for the development of antibody-dependent cellular cytotoxicity enhanced antibodies.

6 Apr 2011

BioLife Solutions first quarter revenue is $611,000 for March 31, 2011

BioLife Solutions, Inc., a leading developer and manufacturer of clinical grade biopreservation media products for cells and tissues, today announced preliminary revenue of $611,000 for its first quarter ended March 31, 2011.

6 Apr 2011

Under stressful conditions, presence of high levels of HER2 protein causes a decrease in autophagy

Research from The Cancer Institute of New Jersey (CINJ) on biological pathways that govern progression and treatment responsiveness of HER2 positive breast cancer is being presented at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) being held in Orlando this week. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

6 Apr 2011

AMPK suppression and SREBP activation are root cause of fatty liver and hyperlipidemia in type 2 diabetes

Researchers from Boston University School of Medicine, including Yu Li, PhD, and other colleagues, have demonstrated that a nutrient sensing pathway is involved in the disruption of cellular lipid homeostasis in obese and insulin resistant mice fed a diet high in fat and sucrose.

6 Apr 2011

High clusterin levels linked to Alzheimer's prevalence and severity

Higher levels in blood of the protein clusterin, also known as apolipoprotein J, are significantly associated with the prevalence and severity of Alzheimer's disease, but not with the risk of onset of new disease, according to a study in the April 6 issue of JAMA.

6 Apr 2011

Nanotechnology can help better assess whether cancer drugs hit their targets

A Purdue University biochemist has demonstrated a process using nanotechnology to better assess whether cancer drugs hit their targets, which may help reduce drug side effects.

6 Apr 2011

Avila's PI3Kα inhibitor preclinical study data presented at AACR meeting

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today presented results of preclinical studies on its novel Phosphoinositide 3-kinase alpha inhibitor at the American Association for Cancer Research 102nd Annual Meeting in Orlando, Florida.

6 Apr 2011

Expression of key tumor suppressor protein induces premature aging

Cancer risk increases with age, and scientists have long perceived a possible evolutionary tradeoff between longer lifespan and greater risk of cancer. Now, researchers at Fox Chase Cancer Center find direct evidence for that tradeoff in new data showing that expression of a key tumor suppressor protein induces premature aging in mice.

6 Apr 2011

Neurotech’s NT-501 intraocular implant slows progression of vision loss in GA subjects

Neurotech Pharmaceuticals, Inc., today announced that it was reported in the Proceedings of the National Academy of Sciences that its product candidate NT-501 slowed progression of vision loss in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) in a Phase 2 study.

6 Apr 2011

NEB, Sequenom sign deal to commercialize research tools for epigenetics

New England Biolabs, Inc. and Sequenom, Inc. jointly announce that they have signed a licensing and co-marketing agreement to commercialize research tools for epigenetics.

From New England Biolabs 6 Apr 2011